| telcagepant (MK-0974) / Merck (MSD) |
NCT00442936: Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) |
|
|
| Completed | 3 | 1380 | NA | Telcagepant potassium 150 mg, Telcagepant potassium 300 mg, Zolmitriptan 5 mg, Placebo to telcagepant 150 mg, Placebo to tecagepant 300 mg, Placebo to zolmitriptan 5 mg, Rescue medication | Merck Sharp & Dohme LLC | Migraine | 10/07 | 10/07 | | |
| Completed | 3 | 1703 | US | MK0974 50 mg, MK0974, MK0974 150 mg, MK0974 300 mg, Comparator: Placebo | Merck Sharp & Dohme LLC | Migraine | 12/07 | 12/07 | | |
NCT00443209: Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012) |
|
|
| Completed | 3 | 1068 | NA | Telcagepant 300 mg soft gel capsules, Telcagepant 280 mg tablets, Rizatriptan 10 mg tablets, Placebo to telcagepant capsules, Placebo to telcagepant tablets, Placebo to rizatriptan tablets | Merck Sharp & Dohme LLC | Migraine | 01/09 | 01/09 | | |
NCT00483704: Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031) |
|
|
| Completed | 3 | 1935 | NA | Telcagepant 140 mg, Talcagepant 280 mg, Placebo | Merck Sharp & Dohme LLC | Migraines | 03/09 | 03/09 | | |
NCT00662818: Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034) |
|
|
| Completed | 3 | 165 | NA | Telcagepant, Acetaminophen/Paracetamol, Placebo to Telcagepant, Placebo to Acetaminophen/Paracetamol | Merck Sharp & Dohme LLC | Migraine Disorders, Heart Disease, Cerebrovascular Accident, TIA (Transient Ischemic Attack), Vascular Diseases, Peripheral Vascular Diseases | 09/09 | 09/09 | | |
NCT01125774: Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065) |
|
|
| Completed | 2/3 | 4548 | NA | Telcagepant, MK-0974, Placebo | Merck Sharp & Dohme LLC | Migraine | 04/11 | 04/11 | | |
